Massachusetts College of Pharmacy & Health Science

NEW YORK, Jan. 10, 2024 /PRNewswire/ -- The American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization, is pleased to announce its 2024 National Board of Directors. Board members oversee the organization's efforts to empower the public through suicide prevention research, education, support and advocacy. "Suicide is one of our nation's leading, yet preventable causes of death. It's through the leadership and dedication of those who serve on the National Board that AFSP will advance suicide prevention in our country," said AFSP Chief Executive Officer Robert Gebbia. "We would like to congratulate our new National Board of Directors members and thank them for volunteering their time, expertise, and passion to save lives and bring hope to those affected by suicide." Four new members are joining the National Board of Directors in 2024 bringing the total membership to 26 with each member serving at least one three-year term. Newly elected members: Holly Wilcox, PhD, MA, professor, Department of Mental Health, Johns Hopkins Bloomberg School of Public Health Doug Middleton, NFL veteran, suicide prevention advocate; founder, Dream the Impossible Dennis Lasley, 911 dispatch lead, Anchorage Police Department Dan Egan, chair, AFSP Capital Region New York Chapter The election of these new members took place in December of 2023. Members appointed to new positions: Lisa Riley, MPH, PA-C, DFAAPA, assistant professor Massachusetts College of Pharmacy and Health Sciences; vice chair, AFSP National Board of Directors Dan Egan, chair, AFSP Loss and Healing Council Dennis Lasley, chair, AFSP Chapter Leadership Council Members completing their term: Erika Barber, MAT, CCLS, manager of training and development, Central States Funds Tony Cornelius, live host, Soul Train Cruise-StarVista; multi-media personality, executive producer, mental health advocate Nancy Farrell, MPA, chief executive officer, Regina Villa Associates Denisse Lammas, LCSW, founder and CEO, Hispanic Family Counseling Michale Lindsey, PhD, MSW, Dean and Paulette Goddard professor of social work, New York University Jerrold Rosenbaum, MD, psychiatrist-in-chief emeritus, director Center for Anxiety and Traumatic Stress Disorders, Massachusetts General Hospital Steve Siple, MBA The organization thanks these outgoing board members for their service. The American Foundation for Suicide Prevention is dedicated to saving lives and bringing hope to those affected by suicide, including those who have experienced a loss. AFSP creates a culture that's smart about mental health through public education and community programs, develops suicide prevention through research and advocacy, and provides support for those affected by suicide. Led by CEO Robert Gebbia and headquartered in New York, with a public policy office in Washington, DC, AFSP has local chapters in all 50 states, DC and Puerto Rico, with programs and events nationwide. Learn more about AFSP in its latest Annual Report and join the conversation on suicide prevention by following AFSP on Facebook, Twitter, Instagram, YouTube and TikTok. Please fill out this press request form with media inquiries. SOURCE American Foundation for Suicide Prevention

AHMEDABAD, India, Oct. 16, 2023 /PRNewswire/ -- Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as 'Zydus') a discovery-driven, global lifesciences company announced the appointment of Mr. Punit Patel as President and Chief Executive Officer, Americas. He will be responsible for the business operations of all Zydus entities in North America which include generics, injectables and specialty business, rare and orphan disease portfolio and also future forays into novel therapeutics. He will be based out of the group's office in Pennington, New Jersey, U.S. Continue Reading Mr. Punit Patel, President & CEO, Americas, Zydus Group A licensed pharmacist who earned his Doctorate of Pharmacy from Massachusetts College of Pharmacy and Allied Health Sciences, Mr. Punit Patel has more than 20 years of experience in the generics and branded pharmaceutical marketplace. His deep understanding of the complex generic pharmaceutical market (specialty, 505b2, injectables & biosimilars), coupled with his people leadership and results-driven style, unlocks value by enabling long-term strategy to be translated into actionable plans. Speaking on the development, Mr. Punit Patel said, "For two decades, Zydus has been contributing with a patient-centric approach to the healthcare spectrum in the U.S., addressing the twin aspects of access and affordability. I look forward to joining Zydus and creating new avenues for growth. As the company leverages its expertise across different portfolios ranging from generics to specialty business and innovation-driven novel therapeutics, it's going to be an exciting journey ahead for Zydus." Prior to his joining Zydus, Mr. Punit Patel was the President of Red Oak Sourcing, helming a multi-billion-dollar generic portfolio. He was overseeing all aspects of Red Oak's business including setting and implementing the strategic roadmap, overseeing supplier relationships, managing financial obligations, transforming company culture and collaborating with the company's stakeholders – CVS Health, Cardinal Health and OptumRx. Under his leadership, Red Oak was recognized as a Great Place to Work for the first time since its inception. Mr. Punit Patel has also worked at Novartis Vaccines & Diagnostics and CVS Caremark. "We look forward to Punit joining our organisation," said Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., "As a seasoned and successful business leader, Punit brings rich and varied experience in healthcare and pharmaceuticals to lead Zydus into the future. Building on the strong foundation that has already been laid, we hope to hone our strategic direction, build and nurture new relationships which will help Zydus grow and strengthen its presence in North America." About Zydus Zydus Lifesciences Ltd., is an innovative, global lifesciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies with an overarching purpose of empowering people with the freedom to live healthier and more fulfilled lives. The group employs 25,000 people worldwide, including 1,400 scientists engaged in R&D and is driven by its mission to unlock new possibilities in lifesciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries. For more details, visit Photo: Logo: SOURCE Zydus Lifesciences Limited

SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc. (“Ambrx” or the “Company”) (NASDAQ: AMAM), today announced the appointment of Renu Vaish, M.Sc., as Chief Regulatory Officer. Ms. Vaish will be responsible for overseeing and designing the Company’s global regulatory strategy and will report to the Company’s President and Chief Executive Officer, Daniel J. O’Connor. Ms. Vaish is an experienced leader in U.S. and global regulatory affairs with extensive experience in oncology drug development ranging from pre-clinical to commercial products in many fields, including prostate and breast cancer. She has held senior regulatory leadership positions at Celgene, Merck and Kite Pharma, as well as other biopharma companies. Most recently, she served as the Senior Vice President, Regulatory Affairs at SpringWorks Therapeutics. Ms. Vaish brings a strong business acumen and technical ability that will be used to leverage strategic thinking into innovative regulatory solutions at Ambrx. She has a demonstrated ability to adapt quickly in challenging and dynamic environments while leading through periods of organizational growth. Her successful track record of achieving results in a variety of diverse, global regulatory and quality settings will be a significant asset to Ambrx. Ms. Vaish has a Master of Science in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences and a Bachelor of Science in Cell and Molecular Biology, from Concordia University. “Renu’s extensive regulatory background and her experience in designing global regulatory strategy for multiple biopharma companies will be an important asset to Ambrx as we progress our core ADC product candidates, ARX788 and ARX517, through the clinical trial process,” said Mr. O’Connor. Renu Vaish, M.Sc., added: “I am excited and honored to be joining Ambrx at this time and very much look forward to working with my colleagues on the continued development of potentially transformative medicines for patients.” In connection with her appointment, Renu Vaish received a one-time inducement award of 2,600,000 ordinary share options, or the equivalent of 371,428 American Depository Shares, which vest over three years. The Company approved the award as an inducement material to Ms. Vaish entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4). About Ambrx Biopharma Inc. Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. In addition, Ambrx has preclinical and clinical collaborations with multiple partners on drug candidates generated using Ambrx technology. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology. For more information, please visit Ambrx routinely posts information that may be important to investors on its website. Forward-Looking Statements This press release includes certain “forward-looking statements” intended to qualify for the “safe harbor” from liability established by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements may be identified by the words “intend,” “plan,” and similar expressions. Forward-looking statements are based on Ambrx’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the continuing impact of the COVID-19 pandemic and other public health-related risks and events on Ambrx’s business, operations, strategy, goals and anticipated milestones; Ambrx’s ability to execute on its strategy including with respect to the timing of its R&D efforts, initiation of clinical trials and other anticipated milestones; risks associated with development and marketing approval of novel therapeutics, including potential delays in clinical trials and regulatory submissions and the fact that future clinical trial results/data may not be consistent with interim, initial or preliminary results/data or results/data from prior preclinical studies or clinical trials; Ambrx’s ability to fund operations as anticipated; and the additional risks and uncertainties set forth more fully under the caption “Risk Factors” in Ambrx’s Quarterly Report on Form 10-Q filed with the SEC on May 11, 2023, and elsewhere in Ambrx’s filings and reports with the SEC, including the prospectus supplement to be filed in connection with the Offering. Forward-looking statements contained in this press release are made as of this date, and Ambrx undertakes no duty to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. Contacts INVESTORS Mike Moyer LifeSci Advisors 617-308-4306 mmoyer@lifesciadvisors.com MEDIA Mike Tattory Account Supervisor LifeSci Communications media@ambrx.com Source: Ambrx Biopharma Inc.